Immunome's Desmoid Tumor Drug Shows 84% Success in Trial

Immunome's (IMNM) Varegacestat reduces disease progression by 84% in Phase 3 desmoid tumor trial. FDA submission planned for Q2 2026. Once-daily oral pill.